Target Name: LOC100128164
NCBI ID: G100128164
Review Report on LOC100128164 Target / Biomarker Content of Review Report on LOC100128164 Target / Biomarker
Other Name(s): FHL1 pseudogene 1, transcript variant 1 | FHL1P1 variant 1 | four and a half LIM domains 1 pseudogene

The Role of LOC100128164 as a Potential Drug Target or Biomarker: A Comprehensive Review

LOC100128164, also known as LncRNA NCRMS, is a long non-coding RNA that has gained significant attention in recent years due to its potential involvement in various biological processes and disease states. This article aims to provide an in-depth analysis of LOC100128164 as a potential drug target or biomarker, highlighting its functions and implications in human health and disease.

What is LOC100128164?
LOC100128164 is a non-protein-coding RNA that does not encode for any functional protein. Despite not producing a protein product, it plays a crucial role in the regulation of gene expression, both at the transcriptional and post-transcriptional levels. LOC100128164 is a highly conserved RNA molecule found in various species, including humans, mice, rats, and others.

The Functions of LOC100128164
Studies have shown that LOC100128164 participates in the regulation of diverse cellular processes, such as cell growth, proliferation, apoptosis, and differentiation. These functions make it a promising candidate for drug target discovery and therapeutic intervention.

LOC100128164 in Cancer
One area where LOC100128164 has gained particular attention is cancer research. Aberrant expression of LOC100128164 has been observed in various types of cancer, including colorectal, breast, lung, and prostate cancer. Additionally, its dysregulation has been associated with tumor progression, metastasis, and drug resistance. Therefore, it holds potential as a biomarker for early cancer detection and as a druggable target.

LOC100128164 as a Potential Drug Target
The unique characteristics and mechanisms of action exhibited by LOC100128164 make it an attractive target for drug development. Researchers have begun exploring different approaches to modulate its activity, with the aim of designing therapeutic interventions that can disrupt cancer cell growth and proliferation. Several studies have shown promising results in preclinical models, opening the door for further investigation and potential clinical applications.

Exploring the Regulatory Mechanisms
A better understanding of the regulatory mechanisms of LOC100128164 is crucial to harness its therapeutic potential fully. Recent studies have revealed that this RNA molecule can interact with other proteins, DNA sequences, and microRNAs, affecting their functions and ultimately impacting cellular processes. Further research is needed to unravel these intricate interactions and identify potential strategies for targeted intervention.

Locating LOC100128164 in Disease States
Apart from cancer, LOC100128164 has also been implicated in other disease states, including neurodegenerative disorders, cardiovascular diseases, and autoimmune conditions. Its dysregulation can influence disease progression and severity, suggesting its potential as a diagnostic or prognostic biomarker. Additionally, targeting LOC100128164 may offer new therapeutic strategies for combating these diseases.

The Challenges Ahead
Although LOC100128164 shows great promise, significant challenges must be addressed before it can be effectively utilized as a drug target or biomarker. The identification of specific inhibitors or activators that can specifically modulate its functions without causing adverse effects remains a significant hurdle. Additionally, large-scale clinical studies are necessary to validate its potential clinical applications and establish its reliability as a biomarker.

LOC100128164, a long non-coding RNA, has emerged as a potential drug target and biomarker in multiple disease states. Its involvement in various cellular processes and its dysregulation in diseases like cancer highlight its significance in human health. Further research and understanding of the regulatory mechanisms of LOC100128164 are essential for unlocking its full therapeutic potential. While challenges exist, the future holds great promise for utilizing LOC100128164 as an effective tool for both diagnosis and treatment in various diseases.

Protein Name: Four And A Half LIM Domains 1 Pseudogene

The "LOC100128164 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100128164 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177 | LOC100133284 | LOC100133331 | LOC100133920 | LOC100134317 | LOC100134368 | LOC100134391 | LOC100134868 | LOC100190986 | LOC100233156 | LOC100240728 | LOC100240734 | LOC100240735 | LOC100271840 | LOC100272216 | LOC100272217 | LOC100286922 | LOC100287036 | LOC100287290 | LOC100287329 | LOC100287413 | LOC100287792 | LOC100287834 | LOC100287846 | LOC100287944 | LOC100288069 | LOC100288162 | LOC100288208 | LOC100288637 | LOC100288656 | LOC100289230